Latest Decision Diagnostics Corp (DECN) Headlines
Post# of 11802
Posted On: 03/09/2014 2:16:09 PM
Latest Decision Diagnostics Corp (DECN) Headlines
Decision Diagnostics Announces Agreement for Funding of Its Prosecution of Anti-Trust and False Advertising Suits Against Division of Johnson & Johnson
Marketwire - Tue Feb 18, 10:25AM CST
Decision Diagnostics Corp. (OTCQB: DECN), the exclusive worldwide sales, service and regulatory processes agent for the popular Shasta GenStrip(TM), the unique Green Glucose Test Strip, specifically designed to work with the Johnson & Johnson's LifeScan Ultra family of glucose testing meters, today announced that that the Company has executed a Terms Agreement with a major east coast based litigation prosecution fund for the financing of the prosecution of DECN's countersuits brought against LifeScan, Inc., a division of Johnson and Johnson, Inc. DECN has asserted claims for anti-trust violations and false advertising.
Decision Diagnostics Announces Agreement for the Funding of Its Prosecution of Anti-Trust and False Advertising Suits Against Division of Johnson & Johnson
Marketwire - Fri Feb 14, 2:30PM CST
Decision Diagnostics Corp. (OTCQB: DECN), the exclusive worldwide sales, service and regulatory processes agent for the popular Shasta GenStrip(TM), the unique Green Glucose Test Strip, specifically designed to work with the Johnson & Johnson's LifeScan Ultra family of glucose testing meters, today announced that that the Company has executed a Terms Agreement with a major east coast based litigation prosecution fund for the financing of the prosecution of DECN's countersuits brought against LifeScan, Inc., a division of Johnson and Johnson, Inc. DECN has asserted claims for anti-trust violations and false advertising.
Decision Diagnostics Announces Posting and Airing of Its New GenStrip Commercial Titled "A Winter Patchwork"
Marketwire - Wed Jan 15, 8:15AM CST
Decision Diagnostics Corp. (OTCBB: DECN), the exclusive worldwide sales, service and regulatory processes agent for the Shasta GenStrip(TM), the Green Glucose Test Strip, specifically designed to work with the Johnson & Johnson's (NYSE: JNJ) LifeScan Ultra family of glucose testing meters, today announced that its Pharma Tech Solutions subsidiary has completed and is airing in many regions in the U.S. its new commercial video titled "GenStrip: A Winter Patchwork." The video is available for viewing at: http://shastagenstrip.com/winter_ad.html or http://youtu.be/j0njOGSSKtQ.
Decision Diagnostics Corp concludes USD12.5m (non-dilutive) credit facility with Platinum Credit Management
M2 - Fri Dec 20, 5:46AM CST
Decision Diagnostics Corp (OTCBB
ECN) reported on Thursday the completion of its USD12.5m revolving credit line with Alpha Credit Resources LLC, a division of Platinum Credit Management LP of New York, NY.
Decision Diagnostics Closes $12.5 Million (Non-Dilutive) Credit Facility With Division of Platinum Credit Management
Marketwire - Thu Dec 19, 8:15AM CST
Decision Diagnostics Corp. (OTCBB: DECN) the exclusive worldwide sales, service and regulatory processes agent for the popular Shasta GenStrip(TM), the unique Green Glucose Test Strip, specifically designed to work with the Johnson & Johnson's (NYSE: JNJ) LifeScan Ultra family of glucose testing meters, today announced that that the Company has closed its agreement for a $12.5 million revolving credit line from Alpha Credit Resources, LLC, a division of Platinum Credit Management LP of New York, NY.
Decision Diagnostics Receives Mandate From U.S. Court of Appeals for the Federal Circuit in the Long Running Dispute With J&J Division
Marketwire - Tue Dec 17, 8:15AM CST
Decision Diagnostics Corp. (OTCBB: DECN), the exclusive worldwide sales, service and regulatory processes agent for the popular Shasta GenStrip(TM), the unique Green Glucose Test Strip, specifically designed to work with the Johnson & Johnson's (NYSE: JNJ) LifeScan Ultra family of glucose testing meters, today announced that on December 11, 2013 the United States Court of Appeals for the Federal Circuit issued its Mandate, making its November 4, 2013 ruling final. Plaintiffs Lifescan Scotland, Ltd, and Lifescan, Inc., divisions of Johnson & Johnson failed to appeal the initial Circuit Court ruling during the statutory period of time allowed, although they still have time to appeal to the U.S. Supreme Court.
Decision Diagnostics Corp's board votes in favour of listing in the premier OTC market tier
M2 - Wed Dec 11, 5:58AM CST
The board of directors of Decision Diagnostics Corp (OTCBB ECN) said on Tuesday that its stock will now be uplisted to the OTC QX, the Premier OTC Market Tier, upon approval.
Decision Diagnostics' Board Votes to Uplist to OTC QX
Marketwire - Tue Dec 10, 8:15AM CST
Decision Diagnostics Corp. (OTCBB: DECN), the exclusive worldwide sales, service and regulatory processes agent for the popular Shasta GenStrip(TM), the unique Green Glucose Test Strip, specifically designed to work with the Johnson & Johnson's (NYSE: JNJ) LifeScan Ultra family of glucose testing meters, today announced that the company's Board of Directors has approved the company's uplisting to the OTC QX, the Premier OTC Market Tier. Concurrent with these Board Resolutions, the company has engaged a sponsoring brokerage and engaged counsel who shall serve as the company's Designated Advisor for Disclosure (DAD).
Decision Diagnostics On Track For Growth and Increased Revenues
ACCESSWIRE - Thu Nov 07, 5:01AM CST
COLORADO, Nov. 7, 2013 - The Shasta GenStrip blood glucose monitoring test strip for in-home use received FDA approval on November 30, 2012. Decision Diagnostics Corp. (OTCBB: DECN) has been fighting a battle to bring the Shasta GenStrip to market ever since and DECN's management is now realizing the fruits of their labor.
DECN and Pharma Tech Solutions Receive Anticipated Ruling from the U.S. Federal Circuit Court of Appeals, Reversing a Ruling by Lower Court Judge
ACCESSWIRE - Tue Nov 05, 8:16AM CST
Washington DC Appeals Court Overturns California Judge in Lynchpin J&J/Lifescan Patent Suit, Citing the Doctrine of Patent Exhaustion
Well Ahead of Schedule, Decision Diagnostic's Pharma Tech Division Completes First Major Shipments of its Popular Genstrip Test Strip
ACCESSWIRE - Thu Oct 31, 8:17AM CDT
genStrip sales powered by changes in medicare and private insurance reimbursements moving demand away from mail order pharmacy models.company to focus on neighborhood pharmacies who can now ensure profit by servicing medicare patients who have lost mail order pharmacy service.chain pharmacy and other large retailers looking to buy genstrip for retail sales and to add genstrip to service the medicare walk-in patients.
Decision Diagnostics Receives Signed Term Sheet Agreement For $12.5 Million Revolving Credit Facility Which Will Complete DECN's GenStrip Roll-Out Plan
ACCESSWIRE - Tue Oct 29, 8:16AM CDT
- New 5-year credit facility amounts to total annual financing of $250+ million
Recognized Healthcare and Financial Publications Acknowledge Decision Diagnostics' GenStrip Market Potential
ACCESSWIRE - Tue Oct 22, 11:50AM CDT
Los Angeles, CA - (October 22, 2013) Decision Diagnostics Corp. (OTCBB: DECN) the exclusive worldwide sales, service and regulatory processes agent for the popular Shasta GenStrip[TM], the unique diabetes monitoring Green Glucose Test Strip, specifically designed to work with the Johnson & Johnson's (JNJ) LifeScan Ultra family of glucose testing meters has been the focus of favorable articles and papers published recently. Today BioMedReports released an article on the front page of their website titled "DECN Set to Climb as GenStrip Enters Blood Glucose Monitoring Market With New Large Shipments." The article summarizes DECN's history and current business. The full article can be read here:
OTC Daily Alert Stock Watch - Decision Diagnostics Corp. (OTCQB: DECN)
WorldStockWire - Tue Sep 17, 6:30PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
Decision Diagnostics Corp. Announces Completion and Airing of Its New Genstrip Video Titled "A Patchwork of Life"
Marketwire - Tue Sep 10, 8:20AM CDT
Decision Diagnostics Corp. (OTCBB: DECN), the exclusive worldwide sales, service and regulatory processes agent for the Shasta GenStrip(TM), the Green Glucose Test Strip, specifically designed to work with the Johnson & Johnson's (NYSE: JNJ) LifeScan Ultra family of glucose testing meters, today announced that its Pharma Tech Solutions subsidiary has completed and is airing its new commercial video titled "Genstrip: A Patchwork of Life." The video is available for viewing at: http://shastagenstrip.com/shasta_ad.html or http://youtu.be/zzBuHxb-rlM. The company will publish the media schedule for future airings in the coming days.
Decision Diagnostic's GenStrip Could Change the Blood Glucose Market
Marketwire - Tue Sep 03, 6:56AM CDT
The glucose monitoring industry is growing at 25% annually and could grow to over $30 billion by 2017. Four players dominate the market, with Johnson & Johnson being the market share leader with over 30% market share. J&J's glucose monitoring system is the LifeScan Ultra with consists of LifeScan Ultra meters and test strips and have annual sales over $4 billion but an upstart player, Decision Diagnostics Corp. (OTCBB: DECN), is entering the market with a new low-cost (about 50% lower), high-performance test strip, which could gain significant market share at the expense of the leaders, according to a new report by Equity Brief.
Decision Diagnostics Subsidiary Makes Move and Sues Two Johnson and Johnson Divisions for False Advertising in Ongoing Battle
Marketwire - Thu Aug 01, 8:15AM CDT
Decision Diagnostics Corp. (OTCBB: DECN), the exclusive worldwide sales, service and regulatory processes agent for the Shasta GenStrip(TM), the Green Glucose Test Strip, specifically designed to work with Johnson & Johnson's (NYSE: JNJ) LifeScan Ultra family of glucose testing meters, announced today the filing of counterclaims by its subsidiary Pharma Tech Solutions, Inc. for false and misleading advertising against two of Johnson & Johnson, Inc. ("J&J") wholly owned subsidiaries, Lifescan, Inc., and Lifescan Scotland, LTD (collectively "Lifescan"). The company and its Pharma Tech Solutions, Inc. ("Pharma Tech") subsidiary have been in patent litigation with the Lifescan subsidiaries since September 2011.
DECN Steps Into Role of White Knight by Offering Strategic Version of GenStrip(TM) Exclusively for Medicare Competitive Bidding Program
Marketwire - Wed May 29, 8:15AM CDT
Decision Diagnostics Corp. (OTCBB: DECN), the exclusive worldwide sales, service and regulatory processes agent for the Shasta GenStrip(TM), the Green Test Strip, specifically designed to work with the Johnson & Johnson's (NYSE: JNJ) LifeScan family of glucose testing meters, announced today that the company and its subsidiary PharmaTech Solutions, Inc. have launched a strategically packaged version of the Shasta GenStrip(TM) for sale to companies who service the "direct to patient" fulfillment (mail order and durable medical goods) channels. This channel, estimated to command a share in excess of 25% of all diabetes testing, takes on increased importance as a result of Medicare's mandated competitive bidding, which is anticipated to lower reimbursement of supplies and medical goods for diabetics by approximately 67% beginning July 1, 2013 and thus to lower market diversity in this important and traditional channel.
Decision Diagnostics Corp. and Its Subsidary PharmaTech Solutions Seek to End Pharma Giant's Alleged Restraint of Trade Tactics
Marketwire - Fri Apr 05, 8:20AM CDT
Decision Diagnostics Corp. (OTCBB: DECN), the exclusive world-wide sales, service and regulatory processes agent for the Shasta GenStrip, the revolutionary at-home glucose test strip specifically designed to work with the Johnson & Johnson's LifeScan family of glucose testing meters, announced today that on March 28, 2013 the company and its subsidiary PharmaTech Solutions, Inc. filed antitrust counterclaims against LifeScan, Inc. and LifeScan Scotland Ltd. (collectively, "LifeScan") in a patent action brought by LifeScan (2011cv04494) that is presently pending in the Northern District of California. DECN and PharmaTech are defendants in that action. DECN is a leading provider of prescription and non-prescription diagnostics, home testing products for the chronically ill and a premier developer of revolutionary cell phone centric e-health products and technologies.
Decision Diagnostics Corp. and Its Subsidiary PharmaTech Solutions, Inc. Sue Johnson & Johnson Division LifeScan, Inc. and LifeScan Scotland Ltd. for Antitrust Violations
Marketwire - Thu Apr 04, 11:32AM CDT
Decision Diagnostics Corp. (OTCBB: DECN) the exclusive world-wide sales, service and regulatory processes agent for the Shasta GenStrip, the revolutionary at-home glucose test strip specifically designed to work with the Johnson & Johnson's LifeScan family of glucose testing meters, announced today that on March 28, 2013 the company and its subsidiary PharmaTech Solutions, Inc. filed antitrust counterclaims against LifeScan, Inc. and LifeScan Scotland, Ltd. (collectively, "LifeScan") in a patent action brought by LifeScan (2011cv04494) that is presently pending in the Northern District of California. DECN and PharmaTech are defendants in that action. DECN is a leading provider of prescription and non-prescription diagnostics, home testing products for the chronically ill and a premier developer of revolutionary cell phone centric e-health products and technologies.
Decision Diagnostics Announces Agreement for Funding of Its Prosecution of Anti-Trust and False Advertising Suits Against Division of Johnson & Johnson
Marketwire - Tue Feb 18, 10:25AM CST
Decision Diagnostics Corp. (OTCQB: DECN), the exclusive worldwide sales, service and regulatory processes agent for the popular Shasta GenStrip(TM), the unique Green Glucose Test Strip, specifically designed to work with the Johnson & Johnson's LifeScan Ultra family of glucose testing meters, today announced that that the Company has executed a Terms Agreement with a major east coast based litigation prosecution fund for the financing of the prosecution of DECN's countersuits brought against LifeScan, Inc., a division of Johnson and Johnson, Inc. DECN has asserted claims for anti-trust violations and false advertising.
Decision Diagnostics Announces Agreement for the Funding of Its Prosecution of Anti-Trust and False Advertising Suits Against Division of Johnson & Johnson
Marketwire - Fri Feb 14, 2:30PM CST
Decision Diagnostics Corp. (OTCQB: DECN), the exclusive worldwide sales, service and regulatory processes agent for the popular Shasta GenStrip(TM), the unique Green Glucose Test Strip, specifically designed to work with the Johnson & Johnson's LifeScan Ultra family of glucose testing meters, today announced that that the Company has executed a Terms Agreement with a major east coast based litigation prosecution fund for the financing of the prosecution of DECN's countersuits brought against LifeScan, Inc., a division of Johnson and Johnson, Inc. DECN has asserted claims for anti-trust violations and false advertising.
Decision Diagnostics Announces Posting and Airing of Its New GenStrip Commercial Titled "A Winter Patchwork"
Marketwire - Wed Jan 15, 8:15AM CST
Decision Diagnostics Corp. (OTCBB: DECN), the exclusive worldwide sales, service and regulatory processes agent for the Shasta GenStrip(TM), the Green Glucose Test Strip, specifically designed to work with the Johnson & Johnson's (NYSE: JNJ) LifeScan Ultra family of glucose testing meters, today announced that its Pharma Tech Solutions subsidiary has completed and is airing in many regions in the U.S. its new commercial video titled "GenStrip: A Winter Patchwork." The video is available for viewing at: http://shastagenstrip.com/winter_ad.html or http://youtu.be/j0njOGSSKtQ.
Decision Diagnostics Corp concludes USD12.5m (non-dilutive) credit facility with Platinum Credit Management
M2 - Fri Dec 20, 5:46AM CST
Decision Diagnostics Corp (OTCBB
ECN) reported on Thursday the completion of its USD12.5m revolving credit line with Alpha Credit Resources LLC, a division of Platinum Credit Management LP of New York, NY. Decision Diagnostics Closes $12.5 Million (Non-Dilutive) Credit Facility With Division of Platinum Credit Management
Marketwire - Thu Dec 19, 8:15AM CST
Decision Diagnostics Corp. (OTCBB: DECN) the exclusive worldwide sales, service and regulatory processes agent for the popular Shasta GenStrip(TM), the unique Green Glucose Test Strip, specifically designed to work with the Johnson & Johnson's (NYSE: JNJ) LifeScan Ultra family of glucose testing meters, today announced that that the Company has closed its agreement for a $12.5 million revolving credit line from Alpha Credit Resources, LLC, a division of Platinum Credit Management LP of New York, NY.
Decision Diagnostics Receives Mandate From U.S. Court of Appeals for the Federal Circuit in the Long Running Dispute With J&J Division
Marketwire - Tue Dec 17, 8:15AM CST
Decision Diagnostics Corp. (OTCBB: DECN), the exclusive worldwide sales, service and regulatory processes agent for the popular Shasta GenStrip(TM), the unique Green Glucose Test Strip, specifically designed to work with the Johnson & Johnson's (NYSE: JNJ) LifeScan Ultra family of glucose testing meters, today announced that on December 11, 2013 the United States Court of Appeals for the Federal Circuit issued its Mandate, making its November 4, 2013 ruling final. Plaintiffs Lifescan Scotland, Ltd, and Lifescan, Inc., divisions of Johnson & Johnson failed to appeal the initial Circuit Court ruling during the statutory period of time allowed, although they still have time to appeal to the U.S. Supreme Court.
Decision Diagnostics Corp's board votes in favour of listing in the premier OTC market tier
M2 - Wed Dec 11, 5:58AM CST
The board of directors of Decision Diagnostics Corp (OTCBB
ECN) said on Tuesday that its stock will now be uplisted to the OTC QX, the Premier OTC Market Tier, upon approval. Decision Diagnostics' Board Votes to Uplist to OTC QX
Marketwire - Tue Dec 10, 8:15AM CST
Decision Diagnostics Corp. (OTCBB: DECN), the exclusive worldwide sales, service and regulatory processes agent for the popular Shasta GenStrip(TM), the unique Green Glucose Test Strip, specifically designed to work with the Johnson & Johnson's (NYSE: JNJ) LifeScan Ultra family of glucose testing meters, today announced that the company's Board of Directors has approved the company's uplisting to the OTC QX, the Premier OTC Market Tier. Concurrent with these Board Resolutions, the company has engaged a sponsoring brokerage and engaged counsel who shall serve as the company's Designated Advisor for Disclosure (DAD).
Decision Diagnostics On Track For Growth and Increased Revenues
ACCESSWIRE - Thu Nov 07, 5:01AM CST
COLORADO, Nov. 7, 2013 - The Shasta GenStrip blood glucose monitoring test strip for in-home use received FDA approval on November 30, 2012. Decision Diagnostics Corp. (OTCBB: DECN) has been fighting a battle to bring the Shasta GenStrip to market ever since and DECN's management is now realizing the fruits of their labor.
DECN and Pharma Tech Solutions Receive Anticipated Ruling from the U.S. Federal Circuit Court of Appeals, Reversing a Ruling by Lower Court Judge
ACCESSWIRE - Tue Nov 05, 8:16AM CST
Washington DC Appeals Court Overturns California Judge in Lynchpin J&J/Lifescan Patent Suit, Citing the Doctrine of Patent Exhaustion
Well Ahead of Schedule, Decision Diagnostic's Pharma Tech Division Completes First Major Shipments of its Popular Genstrip Test Strip
ACCESSWIRE - Thu Oct 31, 8:17AM CDT
genStrip sales powered by changes in medicare and private insurance reimbursements moving demand away from mail order pharmacy models.company to focus on neighborhood pharmacies who can now ensure profit by servicing medicare patients who have lost mail order pharmacy service.chain pharmacy and other large retailers looking to buy genstrip for retail sales and to add genstrip to service the medicare walk-in patients.
Decision Diagnostics Receives Signed Term Sheet Agreement For $12.5 Million Revolving Credit Facility Which Will Complete DECN's GenStrip Roll-Out Plan
ACCESSWIRE - Tue Oct 29, 8:16AM CDT
- New 5-year credit facility amounts to total annual financing of $250+ million
Recognized Healthcare and Financial Publications Acknowledge Decision Diagnostics' GenStrip Market Potential
ACCESSWIRE - Tue Oct 22, 11:50AM CDT
Los Angeles, CA - (October 22, 2013) Decision Diagnostics Corp. (OTCBB: DECN) the exclusive worldwide sales, service and regulatory processes agent for the popular Shasta GenStrip[TM], the unique diabetes monitoring Green Glucose Test Strip, specifically designed to work with the Johnson & Johnson's (JNJ) LifeScan Ultra family of glucose testing meters has been the focus of favorable articles and papers published recently. Today BioMedReports released an article on the front page of their website titled "DECN Set to Climb as GenStrip Enters Blood Glucose Monitoring Market With New Large Shipments." The article summarizes DECN's history and current business. The full article can be read here:
OTC Daily Alert Stock Watch - Decision Diagnostics Corp. (OTCQB: DECN)
WorldStockWire - Tue Sep 17, 6:30PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
Decision Diagnostics Corp. Announces Completion and Airing of Its New Genstrip Video Titled "A Patchwork of Life"
Marketwire - Tue Sep 10, 8:20AM CDT
Decision Diagnostics Corp. (OTCBB: DECN), the exclusive worldwide sales, service and regulatory processes agent for the Shasta GenStrip(TM), the Green Glucose Test Strip, specifically designed to work with the Johnson & Johnson's (NYSE: JNJ) LifeScan Ultra family of glucose testing meters, today announced that its Pharma Tech Solutions subsidiary has completed and is airing its new commercial video titled "Genstrip: A Patchwork of Life." The video is available for viewing at: http://shastagenstrip.com/shasta_ad.html or http://youtu.be/zzBuHxb-rlM. The company will publish the media schedule for future airings in the coming days.
Decision Diagnostic's GenStrip Could Change the Blood Glucose Market
Marketwire - Tue Sep 03, 6:56AM CDT
The glucose monitoring industry is growing at 25% annually and could grow to over $30 billion by 2017. Four players dominate the market, with Johnson & Johnson being the market share leader with over 30% market share. J&J's glucose monitoring system is the LifeScan Ultra with consists of LifeScan Ultra meters and test strips and have annual sales over $4 billion but an upstart player, Decision Diagnostics Corp. (OTCBB: DECN), is entering the market with a new low-cost (about 50% lower), high-performance test strip, which could gain significant market share at the expense of the leaders, according to a new report by Equity Brief.
Decision Diagnostics Subsidiary Makes Move and Sues Two Johnson and Johnson Divisions for False Advertising in Ongoing Battle
Marketwire - Thu Aug 01, 8:15AM CDT
Decision Diagnostics Corp. (OTCBB: DECN), the exclusive worldwide sales, service and regulatory processes agent for the Shasta GenStrip(TM), the Green Glucose Test Strip, specifically designed to work with Johnson & Johnson's (NYSE: JNJ) LifeScan Ultra family of glucose testing meters, announced today the filing of counterclaims by its subsidiary Pharma Tech Solutions, Inc. for false and misleading advertising against two of Johnson & Johnson, Inc. ("J&J") wholly owned subsidiaries, Lifescan, Inc., and Lifescan Scotland, LTD (collectively "Lifescan"). The company and its Pharma Tech Solutions, Inc. ("Pharma Tech") subsidiary have been in patent litigation with the Lifescan subsidiaries since September 2011.
DECN Steps Into Role of White Knight by Offering Strategic Version of GenStrip(TM) Exclusively for Medicare Competitive Bidding Program
Marketwire - Wed May 29, 8:15AM CDT
Decision Diagnostics Corp. (OTCBB: DECN), the exclusive worldwide sales, service and regulatory processes agent for the Shasta GenStrip(TM), the Green Test Strip, specifically designed to work with the Johnson & Johnson's (NYSE: JNJ) LifeScan family of glucose testing meters, announced today that the company and its subsidiary PharmaTech Solutions, Inc. have launched a strategically packaged version of the Shasta GenStrip(TM) for sale to companies who service the "direct to patient" fulfillment (mail order and durable medical goods) channels. This channel, estimated to command a share in excess of 25% of all diabetes testing, takes on increased importance as a result of Medicare's mandated competitive bidding, which is anticipated to lower reimbursement of supplies and medical goods for diabetics by approximately 67% beginning July 1, 2013 and thus to lower market diversity in this important and traditional channel.
Decision Diagnostics Corp. and Its Subsidary PharmaTech Solutions Seek to End Pharma Giant's Alleged Restraint of Trade Tactics
Marketwire - Fri Apr 05, 8:20AM CDT
Decision Diagnostics Corp. (OTCBB: DECN), the exclusive world-wide sales, service and regulatory processes agent for the Shasta GenStrip, the revolutionary at-home glucose test strip specifically designed to work with the Johnson & Johnson's LifeScan family of glucose testing meters, announced today that on March 28, 2013 the company and its subsidiary PharmaTech Solutions, Inc. filed antitrust counterclaims against LifeScan, Inc. and LifeScan Scotland Ltd. (collectively, "LifeScan") in a patent action brought by LifeScan (2011cv04494) that is presently pending in the Northern District of California. DECN and PharmaTech are defendants in that action. DECN is a leading provider of prescription and non-prescription diagnostics, home testing products for the chronically ill and a premier developer of revolutionary cell phone centric e-health products and technologies.
Decision Diagnostics Corp. and Its Subsidiary PharmaTech Solutions, Inc. Sue Johnson & Johnson Division LifeScan, Inc. and LifeScan Scotland Ltd. for Antitrust Violations
Marketwire - Thu Apr 04, 11:32AM CDT
Decision Diagnostics Corp. (OTCBB: DECN) the exclusive world-wide sales, service and regulatory processes agent for the Shasta GenStrip, the revolutionary at-home glucose test strip specifically designed to work with the Johnson & Johnson's LifeScan family of glucose testing meters, announced today that on March 28, 2013 the company and its subsidiary PharmaTech Solutions, Inc. filed antitrust counterclaims against LifeScan, Inc. and LifeScan Scotland, Ltd. (collectively, "LifeScan") in a patent action brought by LifeScan (2011cv04494) that is presently pending in the Northern District of California. DECN and PharmaTech are defendants in that action. DECN is a leading provider of prescription and non-prescription diagnostics, home testing products for the chronically ill and a premier developer of revolutionary cell phone centric e-health products and technologies.
(0)
(0)Decision Diagnostics Corp (DECN) Stock Research Links
Scroll down for more posts ▼